Carisma Therapeutics to present efficacy results of Moderna collaboration

Carisma Therapeutics (CARM) will present new findings at the Society for Immunotherapy of Cancer Annual Meeting regarding its first-of-its-kind collaboration with Moderna (MRNA). The collaboration aims to bring together Carisma’s chimeric antigen receptor macrophage – CAR-M – platform with Moderna’s mRNA and lipid nanoparticle technologies to generate and develop in vivo CAR-M therapeutics. The late-breaking presentation demonstrates Carisma’s CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. The pre-clinical data demonstrate feasibility, tolerability, and efficacy against metastatic solid tumors. This novel approach to cancer immunotherapy offers an off-the-shelf solution that has the potential to increase access to CAR-based therapies and will be the basis of CAR-M programs to be developed under the Carisma and Moderna collaboration.